1. Home
  2. ATOS vs SY Comparison

ATOS vs SY Comparison

Compare ATOS & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • SY
  • Stock Information
  • Founded
  • ATOS 2009
  • SY 2013
  • Country
  • ATOS United States
  • SY China
  • Employees
  • ATOS N/A
  • SY N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • SY EDP Services
  • Sector
  • ATOS Health Care
  • SY Technology
  • Exchange
  • ATOS Nasdaq
  • SY Nasdaq
  • Market Cap
  • ATOS 114.5M
  • SY 98.6M
  • IPO Year
  • ATOS 2012
  • SY 2019
  • Fundamental
  • Price
  • ATOS $0.80
  • SY $0.99
  • Analyst Decision
  • ATOS Strong Buy
  • SY Hold
  • Analyst Count
  • ATOS 3
  • SY 1
  • Target Price
  • ATOS $7.00
  • SY $0.80
  • AVG Volume (30 Days)
  • ATOS 678.1K
  • SY 93.4K
  • Earning Date
  • ATOS 03-31-2025
  • SY 03-19-2025
  • Dividend Yield
  • ATOS N/A
  • SY 6.06%
  • EPS Growth
  • ATOS N/A
  • SY 1.45
  • EPS
  • ATOS N/A
  • SY 0.05
  • Revenue
  • ATOS N/A
  • SY $212,139,568.00
  • Revenue This Year
  • ATOS N/A
  • SY $2.13
  • Revenue Next Year
  • ATOS N/A
  • SY $4.64
  • P/E Ratio
  • ATOS N/A
  • SY $20.11
  • Revenue Growth
  • ATOS N/A
  • SY 3.87
  • 52 Week Low
  • ATOS $0.72
  • SY $0.66
  • 52 Week High
  • ATOS $2.31
  • SY $1.42
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 41.00
  • SY 61.15
  • Support Level
  • ATOS $0.79
  • SY $0.92
  • Resistance Level
  • ATOS $0.89
  • SY $0.99
  • Average True Range (ATR)
  • ATOS 0.05
  • SY 0.06
  • MACD
  • ATOS 0.01
  • SY 0.01
  • Stochastic Oscillator
  • ATOS 25.14
  • SY 94.68

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenues from information services fees and reservation services fees from medical aesthetic service providers.

Share on Social Networks: